Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report)’s share price hit a new 52-week high during trading on Wednesday after Bank of America raised their price target on the stock from $18.00 to $21.

Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...

Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

Hims & Hers, a health and wellness platform, is set to introduce at-home lab testing capabilities through the acquisition of ...

BofA raised the firm’s price target on Hims & Hers to $21 from $18 and keeps an Underperform rating on the shares. The firm increased Q4 ...

Key Takeaways Shares of Hims & Hers Health touched a fresh record high in Wednesday trading after the company announced its ...

Shares of Hims & Hers Health Inc ( HIMS 17.50%) are flying higher on Wednesday. The company's stock gained 21.7% as of 2:00 p ...

Hims’s acquisition of Trybe Labs will put it in competition with health industry juggernauts such as Labcorp and Quest ...

What Hims & Hers stock could be witnessing now is a short-squeeze. As its stock began rising sharply, short-sellers move to get out. So over the past week, we’ve seen shares surge 60%. In midday ...

Hims & Hers Health Inc (NYSE:HIMS) shares are soaring Wednesday after the company announced plans to introduce at-home lab ...